<DOC>
	<DOCNO>NCT01870986</DOCNO>
	<brief_summary>This healthy volunteer study evaluate 210 subject receive single sub-cutaneous dose PF-06410293 adalimumab ( United States ) adalimumab ( European Union ) . This study involve sample pharmacokinetics evaluation drug level follow administration PF-06410293 license adalimumab product .</brief_summary>
	<brief_title>Study Of PF-06410293 And Adalimumab In Healthy Subjects ( REFLECTIONS B538-01 )</brief_title>
	<detailed_description />
	<mesh_term>Adalimumab</mesh_term>
	<criteria>Healthy male female ( nonchildbearing potential ) . Healthy define clinically relevant abnormality identify detailed medical history , full physical examination include blood pressure , pulse , ECG , laboratory testing . Evidence history clinically significant infectious , hematological , renal , endocrine , pulmonary gastrointestinal , cardiovascular , hepatic psychiatric , neurologic , autoimmune , allergic disease .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>February 2014</verification_date>
	<keyword>Healthy Volunteers</keyword>
	<keyword>Phase 1</keyword>
	<keyword>PK</keyword>
	<keyword>adalimumab</keyword>
	<keyword>Single-dose</keyword>
	<keyword>Immunology</keyword>
	<keyword>Bioequivalence</keyword>
	<keyword>Biosimilarity</keyword>
	<keyword>Similarity .</keyword>
</DOC>